Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Alpelisib · Piqray, Vijoice

Small molecule · Inhibitor of phosphatidylinositol-3-kinase alpha (PI3Kα) (PIK3CA) · developed by Novartis

Approved FDA, May 2019
NVS Developer

What is Alpelisib?

Alpelisib is an oral inhibitor of phosphatidylinositol-3-kinase, acting predominantly on the PI3Kα isoform encoded by PIK3CA, and thereby suppressing Akt signaling in cells with PIK3CA mutations. It is studied in PIK3CA-related Overgrowth Spectrum (PROS) and is used with fulvestrant in PIK3CA-mutated breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Piqray, Vijoice, BYL719
Drug type
Small molecule
Targets
phosphatidylinositol-3-kinase alpha (PI3Kα) (PIK3CA)
Mechanism
Inhibitor of phosphatidylinositol-3-kinase alpha (PI3Kα) (PIK3CA)
Pathways
PI3K/Akt signaling, estrogen receptor transcription
Therapy area
Oncology
Developer
Novartis (NVS)
FDA status
Approved as Piqray, Vijoice (May 24, 2019), NDA212526 · FDA label
UNII
08W5N2C97Q

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

PIK3CA-related Overgrowth Spectrum (PROS)

Other drugs acting on PIK3CA

More from Novartis

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Alpelisib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.